Using Aptamers for Cancer Biomarker Discovery | Zendy

Daniel Y. Chang | Zendy; Michael Donovan | Zendy; Weihong Tan | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Using Aptamers for Cancer Biomarker Discovery

Author(s) -

Daniel Y. Chang,

Michael Donovan,

Weihong Tan

Publication year - 2013

Publication title -

journal of nucleic acids

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.621

H-Index - 32

eISSN - 2090-021X

pISSN - 2090-0201

DOI - 10.1155/2013/817350

Subject(s) - aptamer , systematic evolution of ligands by exponential enrichment , biomarker discovery , computational biology , oligonucleotide , biomarker , cancer biomarkers , dna microarray , biology , cancer , computer science , nanotechnology , dna , proteomics , rna , microbiology and biotechnology , genetics , gene , materials science , gene expression

Aptamers are single-stranded synthetic DNA- or RNA-based oligonucleotides that fold into various shapes to bind to a specific target, which includes proteins, metals, and molecules. Aptamers have high affinity and high specificity that are comparable to that of antibodies. They are obtained using iterative method, called (Systematic Evolution of Ligands by Exponential Enrichment) SELEX and cell-based SELEX (cell-SELEX). Aptamers can be paired with recent advances in nanotechnology, microarray, microfluidics, and other technologies for applications in clinical medicine. One particular area that aptamers can shed a light on is biomarker discovery. Biomarkers are important in diagnosis and treatment of cancer. In this paper, we will describe ways in which aptamers can be used to discover biomarkers for cancer diagnosis and therapeutics.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research